Cite
HARVARD Citation
Ksienski, D. et al. (2020). Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. Journal of geriatric oncology. 11 (5), pp. 807-813. [Online].